{"id":"NCT01621191","sponsor":"Eli Lilly and Company","briefTitle":"An Extension Study of Duloxetine in Fibromyalgia (Extension of F1J-JE-HMGZ, NCT01552057)","officialTitle":"An Open Label Extension Study of Phase 3 Trial of Duloxetine in Patients With Fibromyalgia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06","primaryCompletion":"2014-02","completion":"2014-02","firstPosted":"2012-06-18","resultsPosted":"2015-02-11","lastUpdate":"2015-02-11"},"enrollment":149,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Fibromyalgia"],"interventions":[{"type":"DRUG","name":"Duloxetine","otherNames":["LY248686","Cymbalta","Ariclaim","Xeristar","Yentreve"]}],"arms":[{"label":"60 mg Duloxetine","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to assess the safety and efficacy of duloxetine in participants with fibromyalgia at long-term use.","primaryOutcome":{"measure":"Number of Participants Who Experienced an Adverse Event (AE)","timeFrame":"Baseline through 53 weeks","effectByArm":[{"arm":"Duloxetine 60 mg","deltaMin":138,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":13},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":149},"commonTop":["Nasopharyngitis","Somnolence","Constipation","Nausea","Weight increased"]}}